<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28824/keynote-240-outcomes-presented-at-asco-2019?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

KEYNOTE-240 Outcomes Presented at ASCO 2019

Name: KEYNOTE-240 Outcomes Presented at ASCO 2019
Uploaded: 2019-06-26T08:34:16
Duration: 1 min 15 s
Description: Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC).

00:01:15

Don

3 years 129 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28824/keynote-240-outcomes-presented-at-asco-2019?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28824/keynote-240-outcomes-presented-at-asco-2019?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28824/keynote-240-outcomes-presented-at-asco-2019?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28824?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190626203416_bf27/video_190626203416_bf27.jpg?cache=15669161561678829655">KEYNOTE-240  Outcomes Presented at ASCO 2019</a>

Link (BBCode):

[url=https://oncologytube.com/v/28824?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190626203416_bf27/video_190626203416_bf27.jpg?cache=15669161561678829655[/img]KEYNOTE-240  Outcomes Presented at ASCO 2019[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Other

Description:

Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC).